MinervaX Strengthens Executive Leadership Team with Two Strategic Appointments as it Advances its Maternal GBS Vaccine Towards Pivotal Trial Initiation

on

MinervaX, a Danish biotechnology company, announced on April 15, 2026, the appointments of Jamila Louahed as Chief Development Officer (CDO) from GSK with over 20 years in vaccine development, and Hans Henrik Chrois Christensen as Chief Financial Officer (CFO) with extensive life science financial leadership.12

These appointments support MinervaX's preparation for pivotal trial initiation of its maternal GBS vaccine, building on robust Phase II results and surrogate efficacy markers.12

The protein-only GBS vaccine targets fusions from the Alpha-like protein family (AlpN) for broad protection against nearly all GBS strains, addressing a global burden of 410,000 cases and 147,000 stillbirths/infant deaths annually, with no approved vaccines available.12

MinervaX is also advancing the vaccine for older adults after completing Phase I.12

CEO Per Fischer highlighted the expertise for executing long-term ambitions in preventing GBS infections.12

Sources:

1. https://www.globenewswire.com/news-release/2026/04/15/3274157/0/en/MinervaX-Strengthens-Executive-Leadership-Team-with-Two-Strategic-Appointments-as-it-Advances-its-Maternal-GBS-Vaccine-Towards-Pivotal-Trial-Initiation.html

2. https://bebeez.eu/2026/04/15/danish-minervax-bolsters-executive-team-amid-transition-to-pivotal-vaccine-trial-phase/